Nasdaq Cancels Delisting Hearing For Apollomics, Confirms Compliance With Continued Listing Standards

Author: Benzinga Newsdesk | October 15, 2025 01:40pm

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notifying Apollomics the Staff had determined that the Company is in compliance with Nasdaq's continued listing requirements. Accordingly, Nasdaq has cancelled its appeal hearing and the Company's securities will remain listed and continue to trade on The Nasdaq Stock Market.

Posted In: APLM